Margaret A. Shipp, MD, is the Douglas S. Miller Chair in Lymphoma and Chief of the Division of Hematologic Neoplasia in the Department of Medical Oncology at Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School. She received her Doctor of Medicine from Washington University School of Medicine, and completed an Internal Medicine internship and residency at Barnes Hospital/Washington University, and a Fellowship in Medical Oncology before joining the faculty. Her clinical and laboratory research focuses on the clinical and molecular heterogeneity of the large B-cell lymphomas (LBCLs) and Hodgkin lymphomas. She coordinated the development of the International Prognostic Index which is used to individualize treatment approaches to LBCLs and many other lymphoid malignancies. More recently, she has led efforts to define molecular signatures of LBCLs and Hodgkin lymphomas, identify genetically and biologically distinct subsets of these diseases, and characterize associated rational treatment targets including modulators of the host anti-tumor immune response. She is the recipient of awards including membership in the American Society of Clinical Investigation, Association of American Physicians and the National Academy of Medicine, the Gianni Bonadonna Memorial Lecture at the Fourteenth International Conference on Malignant Lymphoma, the John Ultmann Award for Contributions to Lymphoma Research and Treatment, the DFCI Medical Oncology Discovery Award and the San Salvatore Award at the Seventeenth ICML.